SCHEMBL2956483

SCHEMBL2956483

CC(C)S.[NaH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5250 0.93
SCHEMBL31543707 0.86
SCHEMBL29568674 0.86
SCHEMBL28542041 0.86
Potassium SCHEMBL1581738 0.86 ALDH1A1 (0.33)
Ammonia Solution, Strong SCHEMBL28551190 0.86
SCHEMBL7659527 0.86
SCHEMBL1525899 0.86
SCHEMBL8031293 0.86
Hydrogen Sulfide SCHEMBL5307382 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105085434-B The preparation method of tietylperazine or wherein mesosome 上海特化医药科技有限公司 2018-02-09 CN claimed
CN-116969925-B Heteroaryl-triazole compounds BAYER AG (DE) 2026-05-26 CN disclosed
EP-3805232-B1 CRYSTALLINE SYNTHETIC INTERMEDIATE USEFUL IN PROCESSES FOR MAKING A MDM2 INHIBITOR AMGEN INC (US) 2026-04-22 EP disclosed
US-20250295647-A1 PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR AMGEN INC. (US) 2025-09-25 US disclosed
CN-119143747-A Heteroaromatic ring structure compound, pharmaceutical composition and application thereof 上海璎黎药业有限公司 2024-12-17 CN disclosed
CN-117510503-A Tyrosine threonine kinase PKMYT1 inhibitor 成都先导药物开发股份有限公司 2024-02-06 CN disclosed
CN-113121395-B Synthesis of monofunctional thiuram accelerators 固特异轮胎和橡胶公司 2023-10-31 CN disclosed
EP-3845520-B1 SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR GOODYEAR TIRE & RUBBER (US) 2023-10-25 EP disclosed
CN-116925043-A Heteroaryl-triazole compounds 拜耳公司 2023-10-24 CN disclosed
US-20230301974-A1 PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR AMGEN INC. (US) 2023-09-28 US disclosed
EP-0603229-B1 QUINUCLIDINE ESTERS PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER LTD (GB) 1998-06-10 EP disclosed
CN-1037269-C Therapeutic compounds PFIZER (US) 1998-02-04 CN disclosed
CN-1168377-A Novel buprenophine analgesic analogues DONG KOOK PHARM CO LTD (KR) 1997-12-24 CN disclosed
US-5543419-A TREATING CHRONIC OBSTRUCTIVE AIRWAYS DISEASE OR ASTHMA; ANTIMUSCARINIC BRONCHODILATOR AGENTS PFIZER INC (US) 1996-08-06 US disclosed
EP-0603229-A1 QUINUCLIDINE ESTERS PROCESS AND INTERMEDIATE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Pfizer Limited (GB) 1994-06-29 EP disclosed
CN-1087092-A Novel 7 beta-substituted-4-aza-5 alpha-androstan-3-ones as 5 alpha-reductase inhibitors MERCK & CO INC (US) 1994-05-25 CN disclosed
CN-1070911-A The treatment compound PFIZER (US) 1993-04-14 CN disclosed
WO-1993006098-A1 QUINUCLIDINE ESTERS PROCESS AND INTERMEDIATE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER LIMITED (GB) 1993-04-01 WO disclosed
US-5093370-A Useful prior to insertion of tracheotomy tube or discission TOBISHI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1992-03-03 US disclosed
CN-1039028-A The preparation method of novel cpd HAESSLE AB (SE) 1990-01-24 CN disclosed